<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812448459</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812448459</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Late Infantile Neuronal Ceroid Lipofuscinosis</article-title>
<subtitle>Mutations in the <italic>CLN2</italic> Gene and Clinical Course in Spanish Patients</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pérez-Poyato</surname>
<given-names>María S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812448459">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marfa</surname>
<given-names>Mercé Pineda</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0883073812448459">1</xref>
<xref ref-type="aff" rid="aff2-0883073812448459">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abizanda</surname>
<given-names>Isidre Ferrer</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0883073812448459">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>Laia</given-names>
</name>
<degrees>BS, PhD</degrees>
<xref ref-type="aff" rid="aff2-0883073812448459">2</xref>
<xref ref-type="aff" rid="aff4-0883073812448459">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sánchez</surname>
<given-names>Victoria Cusí</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff5-0883073812448459">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González</surname>
<given-names>María J Martínez</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff6-0883073812448459">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Puñal</surname>
<given-names>Jesús Eiris</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff7-0883073812448459">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pérez</surname>
<given-names>Alfonso Verdú</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff8-0883073812448459">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>González</surname>
<given-names>M Mar García</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff9-0883073812448459">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bermejo</surname>
<given-names>Antonio Martínez</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff10-0883073812448459">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hernández</surname>
<given-names>Elena Martín</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff11-0883073812448459">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosell</surname>
<given-names>M Josep Coll</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff12-0883073812448459">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gort</surname>
<given-names>Laura</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0883073812448459">2</xref>
<xref ref-type="aff" rid="aff12-0883073812448459">12</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Milá</surname>
<given-names>Montserrat</given-names>
</name>
<degrees>BS, PhD</degrees>
<xref ref-type="aff" rid="aff2-0883073812448459">2</xref>
<xref ref-type="aff" rid="aff4-0883073812448459">4</xref>
<xref ref-type="corresp" rid="corresp1-0883073812448459"/>
</contrib>
</contrib-group>
<aff id="aff1-0883073812448459">
<label>1</label>Department of Pediatric Neurology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain</aff>
<aff id="aff2-0883073812448459">
<label>2</label>Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Spain</aff>
<aff id="aff3-0883073812448459">
<label>3</label>Institute of Neuropathology, Service of Anatomical Pathology, IDIBELL-Hospital Universitari de Bellvitge, Barcelona, CIBERNED, Spain</aff>
<aff id="aff4-0883073812448459">
<label>4</label>Biochemical and Molecular Genetics Department, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Spain</aff>
<aff id="aff5-0883073812448459">
<label>5</label>Service of Anatomical Pathology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain</aff>
<aff id="aff6-0883073812448459">
<label>6</label>Department of Pediatric Neurology, Hospital Cruces, Baracaldo, Bizkaia, Spain</aff>
<aff id="aff7-0883073812448459">
<label>7</label>Department of Pediatric Neurology, Hospital Clínico Santiago de Compostela, Spain</aff>
<aff id="aff8-0883073812448459">
<label>8</label>Department of Pediatric Neurology, Hospital Virgen de la Salud, Toledo, Spain</aff>
<aff id="aff9-0883073812448459">
<label>9</label>Department of Pediatric Neurology, Hospital de Figueras, Girona, Spain</aff>
<aff id="aff10-0883073812448459">
<label>10</label>Department of Pediatric Neurology, Hospital La Paz, Madrid, Spain</aff>
<aff id="aff11-0883073812448459">
<label>11</label>Department of Pediatric Neurology, Pediatric Unit of rare disease, Hospital 12 de Octubre, Madrid, Spain</aff>
<aff id="aff12-0883073812448459">
<label>12</label>Biochemical and Molecular Genetics Department, Inborn Errors of Metabolism (IBC), Hospital Clínic, Barcelona, Spain</aff>
<author-notes>
<corresp id="corresp1-0883073812448459">Montserrat Milá Recasens, PhD, Biochemical and Molecular Genetics Department, IDIBAPS, Hospital Clinic, Universitat de Barcelona, Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Carrer Villarroel, 170, Barcelona 08036, Spain. Email: <email>MMILA@clinic.ub.es</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>470</fpage>
<lpage>478</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Late infantile neuronal ceroid lipofuscinosis (Jansky-Bielchowsky disease) is a rare disease caused by mutations in the <italic>CLN2 </italic>gene. The authors report the clinical outcome and correlate with genotype in 12 Spanish patients with this disease. Psychomotor regression, epilepsy, and other clinical symptoms/signs were assessed. Age at onset of clinical symptoms ranged from 18 months to 3.7 years, and they included delayed speech and simple febrile seizures followed by epilepsy. Partial seizures and myoclonic jerks occurred at an earlier age (median 3.4 and 3.7 years, respectively) than ataxia and cognitive decline (median 4 years). Clinical regression was initiated by loss of sentences (median 3.7 years) followed by loss of walking ability and absence of language (median 4.5 years). Patients showed blindness and lost sitting ability at similar age (median 5 years). The authors report 4 novel mutations in the <italic>CLN2</italic> gene. This study provides detailed information about the natural history of this disease.</p>
</abstract>
<kwd-group>
<kwd>clinical outcome</kwd>
<kwd>
<italic>CLN2</italic> gene</kwd>
<kwd>Jansky-Bielschowsky disease</kwd>
<kwd>late infantile neuronal ceroid lipofuscinosis</kwd>
<kwd>tripeptidyl peptidase 1</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Neuronal ceroid lipofuscinosis is one of the most common groups of progressive neurodegenerative diseases in childhood.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812448459">1</xref>
</sup> Late infantile neuronal ceroid lipofuscinosis (Jansky-Bielchowsky disease) is the second most frequent form of the 8 neuronal ceroid lipofuscinosis lysosomal storage disorders<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448459">2</xref>
</sup> all of which are genetically determined diseases.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812448459">3</xref>
</sup> Eight causal genes, <italic>CLN10/CTSD, CLN1/PPT, CLN2/TTP1, CLN3, CLN5, CLN6, CLN7/MFSD8, CLN8, </italic>have been identified in childhood (http://www.ucl.ac.uk/ncl/mutation.shtml).</p>
<p>Late infantile neuronal ceroid lipofuscinosis is rare with an incidence of 0.46 per 100 000 live births in West Germany<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448459">4</xref>
</sup> and an estimated prevalence of 0.6 to 0.7 per 1 000 000 in Northern Europe.<sup>
<xref ref-type="bibr" rid="bibr5-0883073812448459">5</xref>
</sup> It is caused by mutations in the <italic>CLN2</italic> gene, located on chromosome 11q15,<sup>
<xref ref-type="bibr" rid="bibr6-0883073812448459">6</xref>
</sup> which encodes the lysosomal enzyme tripeptidyl peptidase 1.<sup>
<xref ref-type="bibr" rid="bibr7-0883073812448459">7</xref>
</sup> Ultrastructural examination of late infantile neuronal ceroid lipofuscinosis storage bodies reveals curvilinear bodies (CV) in cells of affected individuals.<sup>
<xref ref-type="bibr" rid="bibr8-0883073812448459">8</xref>
</sup> Clinically, late infantile neuronal ceroid lipofuscinosis is characterized by epilepsy at the age of 2 to 4 years, which may be manifested by partial or secondary generalized seizures as well as generalized tonic-clonic or absence seizures, but myoclonus is the most characteristic feature. Sometimes delayed speech may precede epilepsy. Regression of acquired skills becomes evident soon thereafter, followed by ataxia, extrapyramidal, and pyramidal signs. Visual failure leads to blindness by 5 or 6 years of age. The patients usually die between 6 and 15 years of age.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812448459">9</xref>,<xref ref-type="bibr" rid="bibr10-0883073812448459">10</xref>
</sup>
</p>
<p>Mutations in the <italic>CLN2</italic> gene may give rise not only to classical late-infantile but also to juvenile onset of the disease with a milder clinical course.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812448459">3</xref>,<xref ref-type="bibr" rid="bibr11-0883073812448459">11</xref>
<xref ref-type="bibr" rid="bibr12-0883073812448459"/>
<xref ref-type="bibr" rid="bibr13-0883073812448459"/>
<xref ref-type="bibr" rid="bibr14-0883073812448459"/>–<xref ref-type="bibr" rid="bibr15-0883073812448459">15</xref>
</sup> Furthermore, patients with onset of the disease in the first year of life have been reported.<sup>
<xref ref-type="bibr" rid="bibr16-0883073812448459">16</xref>,<xref ref-type="bibr" rid="bibr17-0883073812448459">17</xref>
</sup> Two common mutations, the splicing mutation c.509-1G&gt;A and the nonsense mutation c.622 C&gt;T, account for approximately 60% to 78% of patients with late infantile neuronal ceroid lipofuscinosis.<sup>
<xref ref-type="bibr" rid="bibr18-0883073812448459">18</xref>,<xref ref-type="bibr" rid="bibr19-0883073812448459">19</xref>
</sup>
</p>
<p>The clinical features of late infantile neuronal ceroid lipofuscinosis are clearly defined and the progressive deteriorating course of late infantile neuronal ceroid lipofuscinosis has been assessed by clinical rating scores (modified Hamburg Late Infantile Neuronal Ceroid Lipofuscinosis Scale, Weill Cornell Late Infantile Neuronal Ceroid Lipofuscinosis Scale).<sup>
<xref ref-type="bibr" rid="bibr20-0883073812448459">20</xref>,<xref ref-type="bibr" rid="bibr21-0883073812448459">21</xref>
</sup> In this study, we report the clinical outcome and correlate with genotype in 12 Spanish patients with late infantile neuronal ceroid lipofuscinosis.</p>
<sec id="section1-0883073812448459" sec-type="methods">
<title>Patients and Methods</title>
<p>From 1979 to 2011, a total of 12 Spanish patients (8 males, 4 females) with a mean age of 7.4 years (range 4-14) from 10 unrelated families were diagnosed with late infantile neuronal ceroid lipofuscinosis. The study was approved by the Ethics Committee of Hospital Sant Joan de Déu in Barcelona, which was the reference hospital for the study. Written informed consent was obtained from all patients, parents, or legal guardians.</p>
<p>Data from each patient were collected from the patient’s medical record and completed by information provided by the physicians in charge and parents. The review of the medical records and the interviews was conducted by a single investigator. Data were entered into a database previously reported<sup>
<xref ref-type="bibr" rid="bibr22-0883073812448459">22</xref>
</sup> with 50 items that included age at diagnosis; initial symptom; age at regression of acquired skills; type of seizures (myoclonic, myoclonic-atonic, partial, generalized tonic-clonic, secondarily generalized, atypical absence); main signs and symptoms; electroencephalographic findings; ophthalmologic data; electroretinographic findings; visual evoked potentials; enzymatic assays (tripeptidyl peptidase 1); ultrastructural data and molecular studies.</p>
<p>Neurophysiological (electroretinography, visual evoked potentials), neuroimaging (brain magnetic resonance imaging [MRI], computed tomography scanner), and ophthalmologic studies were available for all patients. Electroretinography was performed in 9 patients at least once during the course of the disease. Visual evoked potentials were performed in 7 patients and ophthalmologic evaluations in 11. All patients underwent neuroimaging studies.</p>
<p>Electron microscope examinations of biopsied tissues were the main morphological diagnostic technique being obtained according to routine methods. The histologic examination of biopsy samples was carried out in 9 patients, including biopsies of the skin (4 patients), conjunctiva (2 patients), appendix (2 patients), and muscle (1 patient). The tissue samples were fixed in 2.5% glutaraldehyde in phosphate buffer, postfixed in 1% osmium tetroxide, dehydrated through graded ethanol and embedded in epoxy resin. Semithin sections were stained with toluidine blue and selected ultra-thin sections with uranyl acetate and lead citrate.</p>
<p>Tripeptidyl peptidase 1 activity was measured in samples of leukocytes or fibroblasts of 8 patients. The fluorometric enzymatic analyses were performed using Ala-Ala-Phe-7-amido-4-metilcoumarina (Sigma, Spain) as substrate. Protein measurement was performed according to the method of Lowry et al (1951).<sup>
<xref ref-type="bibr" rid="bibr23-0883073812448459">23</xref>
</sup>
</p>
<p>Molecular genetics studies were carried out in 9 patients. DNA was not available in 3 patients, as 1 patient died before genetic studies were available (case 1) and 1 family did not approve this study (cases 4a and 4b). DNA extraction from whole blood was performed using an automatic MagnaPure system (Roche Diagnostics, Spain) according to the manufacturer’s instructions. The presence of mutations was assessed by direct sequencing of the 13 exons of the <italic>CLN2</italic> gene using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI3130 automatic sequencer (Applied Biosystems).</p>
<p>The primary endpoints of the study were the assessment of psychomotor regression (time to reach regression of acquired skills), epilepsy (age at onset of seizures), and the age at onset of main clinical symptoms/signs of the disease. Nonparametrical survival estimation was performed by means of a Kaplan-Meier analysis. The time variable was computed as the time interval from birth to the onset of psychomotor regression, epilepsy, and clinical symptoms/signs of the disease. In the absence of this information, the follow-up time was censured at the last visit. Data were analyzed with the Statistical Package for the Social Sciences (SPSS) computer program (version 17.0).</p>
</sec>
<sec id="section2-0883073812448459">
<title>Results</title>
<sec id="section3-0883073812448459">
<title>Enzymatic, Molecular Studies, and Ultrastructural Findings</title>
<p>Partial deficiency of tripeptidyl peptidase 1 activity was found in 8 patients, 6 of them also showed mutations in the <italic>CLN2</italic> gene (cases 5, 6, 7, 8a, 8b, and 9). In the remaining 4 patients, data on tripeptidyl peptidase 1 activity were not assessed; 3 of these patients belonged to 3 unrelated families harboring mutations in the <italic>CLN2</italic> gene (cases 2, 3, and 10) and in the remaining patient the diagnosis was made by a typical clinical course compatible with late infantile neuronal ceroid lipofuscinosis and ultrastructural studies that showed curvilinear bodies inclusions (case 1).</p>
<p>Mutations in the <italic>CLN2</italic> gene were present in 10 cases (8 unrelated) (<xref ref-type="table" rid="table2-0883073812448459">Table 2</xref>). The nonsense mutation c.622 C&gt;T leading to R208stop accounted for 20% of the <italic>CLN2</italic> mutated chromosomes and the splicing mutation (IVS5-1G&gt;C) for a 6%.</p>
<p>Electron microscopy examination of biopsies revealed the presence of membrane-bound curvilinear inclusions in various cell types including endothelial cells, pericytes, smooth muscle cells, fibroblasts, Schwann cells, and glands depending on the tissue available for study. Curvilinear inclusions in fibroblast in a case of late infantile neuronal ceroid lipofuscinosis are shown in <xref ref-type="fig" rid="fig1-0883073812448459">Figure 1</xref>.</p>
<fig id="fig1-0883073812448459" position="float">
<label>Figure 1.</label>
<caption>
<p>Curvilinear inclusions in fibroblasts in one case of <italic>CLN2</italic> mutation (ultrathin section stained with uranyl acetate and lead citrate, ×42 000).</p>
</caption>
<graphic alternate-form-of="fig1-0883073812448459" xlink:href="10.1177_0883073812448459-fig1.tif"/>
</fig>
<p>Individualized clinical, enzymatic, and ultrastructural data are shown in <xref ref-type="table" rid="table1-0883073812448459">Table 1</xref>.</p>
<table-wrap id="table1-0883073812448459" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical features, enzymatic and ultrastructural studies in Spanish patients with late infantile neuronal ceroid lipofuscinosis.</p>
</caption>
<graphic alternate-form-of="table1-0883073812448459" xlink:href="10.1177_0883073812448459-table1.tif"/>
<table>
<thead>
<tr>
<th>Case number</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Consan guinity</th>
<th>Presenting symptom </th>
<th>Age at first symptom/age at diagnosis (y) </th>
<th>Seizures (age, y/mo)</th>
<th>Myoclonus jerks/continuous myoclonus (age, y/mo)</th>
<th>Cognitive decline (age, y/mo)</th>
<th>Ataxia (age, y/mo)</th>
<th>Ophthalmologic findings (age, y/mo)</th>
<th>VEP (age, y/mo)</th>
<th>ERG (age, y/mo) </th>
<th>Cerebral/cerebellar atrophy (age, y/mo)</th>
<th>TPP1 activity nmol/h/mg (control)</th>
<th>Electron microscopy (biopsied tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>9<sup>*</sup>
</td>
<td>Yes</td>
<td>Simple febrile seizures</td>
<td>2 / 6</td>
<td>Myoclonic-atonic (3 y 7 mo)</td>
<td>4 y 4 mo/4 y 9 mo</td>
<td>4 y</td>
<td>4 y</td>
<td>Papillary pallor (5 y) Optic nerve atrophy (7 y)</td>
<td>Normal (4 y 9 mo)</td>
<td>Decreased amplitude (4 y 9 mo)</td>
<td>+/+ (5 y)</td>
<td>ND</td>
<td>CV (conjunctive)</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>10<sup>*</sup>
</td>
<td>No</td>
<td>Simple febrile seizures</td>
<td>3.7 / 6</td>
<td>Myoclonic-atonic (4 y 9 mo)</td>
<td>3 y 10 mo/5 y 6 mo </td>
<td>4 y</td>
<td>3 y 10 mo</td>
<td>Papillary pallor (5 y 6 mo)</td>
<td>Giant responses (5 y 3 mo)</td>
<td>↓voltage, (5 y 3 mo)</td>
<td>- /+ (3y 10mo)</td>
<td>ND</td>
<td>CV (appendix)</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>7<sup>*</sup>
</td>
<td>Yes</td>
<td>Delayed speech</td>
<td>2 / 7</td>
<td>Generalized/Partial (3 y 7 mo)</td>
<td>3 y/5 y</td>
<td>3 y 6 mo</td>
<td>3 y 9 mo</td>
<td>Papillary pallor (3 y) Optic nerve atrophy (5 y)</td>
<td>Abolished (5 y 6 mo)</td>
<td>Abolished (5 y 6 mo)</td>
<td>-/+ (3 y 6mo)</td>
<td>ND</td>
<td>CV (appendix)</td>
</tr>
<tr>
<td>4a</td>
<td>M</td>
<td>6<sup>*</sup>
</td>
<td>No</td>
<td>Partial status epilepticus</td>
<td>3.4 / 5</td>
<td>Partial status epilepticus</td>
<td>3 y 7 mo/4 y 3 mo</td>
<td>3 y 7 mo</td>
<td>4 y 2 mo</td>
<td>Papillary pallor (5 y)</td>
<td>Delayed latency (4 y)</td>
<td>Abolished (4 y)</td>
<td>+/+ (5 y)</td>
<td>2.9 (125.1)</td>
<td>CV (skin)</td>
</tr>
<tr>
<td>4b</td>
<td>F</td>
<td>8<sup>*</sup>
</td>
<td>No</td>
<td>Partial seizures</td>
<td>3 / 4</td>
<td>Partial seizures</td>
<td>3 y 9 mo/3 y 11 mo</td>
<td>3 y 6 mo</td>
<td>4 y</td>
<td>ND</td>
<td>ND</td>
<td>Normal (3 y 5 mo)</td>
<td>+/+ (4 y)</td>
<td>0.8 (125.1)</td>
<td>ND</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>14<sup>*</sup>
</td>
<td>No</td>
<td>Simple febrile seizures</td>
<td>1. 6 / 7</td>
<td>Generalized (4 y)</td>
<td>5 y/7 y </td>
<td>5 y 6 mo</td>
<td>5 y 5 mo</td>
<td>Normal (6 y)</td>
<td>ND</td>
<td>ND</td>
<td>+/+ (4 y 9 mo)</td>
<td>9,8 (403)</td>
<td>CV (muscle)</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>6<sup>*</sup>
</td>
<td>No</td>
<td>Delayed speech</td>
<td>2 / 4</td>
<td>Partial (2 y 11 mo)</td>
<td>3 y 7 mo/4 y</td>
<td>3 y 3 mo</td>
<td>3 y 7 mo</td>
<td>Normal (3 y 9 mo)</td>
<td>ND</td>
<td>Normal (3 y 7 mo)</td>
<td>+/+ (3y 3 mo)</td>
<td>1.7 (223)</td>
<td>CV (skin)</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>11</td>
<td>No</td>
<td>Delayed speech</td>
<td>2 / 7</td>
<td>Generalized (3 y 4 mo)</td>
<td>3 y 10 mo/6 y</td>
<td>4 y</td>
<td>4 y</td>
<td>Normal (3 y 4 mo)</td>
<td>Giant responses (3 y 4 mo)</td>
<td>Normal (4 y 5 mo)</td>
<td>–/+ (3 y 4 mo)</td>
<td>21.20 (788.90)</td>
<td>CV (skin)</td>
</tr>
<tr>
<td>8a</td>
<td>M</td>
<td>6<sup>*</sup>
</td>
<td>No</td>
<td>Clumsiness</td>
<td>2 / 6</td>
<td>Partial (3 y 8 mo)</td>
<td>4 y 3 mo/6 y</td>
<td>4 y 3 mo</td>
<td>4 y 6 mo</td>
<td>Peripheral pigmentary clumping (5 y)</td>
<td>Normal (4 y 6 mo)</td>
<td>ND</td>
<td>–/+ (3 y 8 mo)</td>
<td>4.7 (1003.1)</td>
<td>CV (conjunctive)</td>
</tr>
<tr>
<td>8b</td>
<td>F</td>
<td>6<sup>*</sup>
</td>
<td>No</td>
<td>Delayed speech</td>
<td>2 / 2</td>
<td>Partial (3 y 5 mo)</td>
<td>3 y 7 mo/5 y</td>
<td>4 y 10 mo</td>
<td>4 y</td>
<td>Peripheral pigmentary clumping (5 y)</td>
<td>ND</td>
<td>ND</td>
<td>–/+ (3 y 5 mo)</td>
<td>11.3 (1003.1)</td>
<td>ND</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>7</td>
<td>No</td>
<td>Simple febrile seizures</td>
<td>2. 5 / 3</td>
<td>Myoclonic-atonic (2 y 6 mo)</td>
<td>2 y 6 mo/3 y 6 mo</td>
<td>3 y 6 mo</td>
<td>4 y</td>
<td>Normal (3 y)</td>
<td>ND</td>
<td>Normal (3 y 7 mo)</td>
<td>Normal (3 y)</td>
<td>13.10 (674)</td>
<td>ND</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>4</td>
<td>No</td>
<td>Delayed speech</td>
<td>2 / 4</td>
<td>Partial (3 y 3 mo)</td>
<td>3 y 9 mo/4 y</td>
<td>4 y</td>
<td>3 y 9 mo</td>
<td>Papillary pallor (3 y 10 mo)</td>
<td>↓ voltage (3 y 9 mo)</td>
<td>↓ voltage (3 y 9 mo)</td>
<td>–/+ (3 y 4 mo)</td>
<td>ND</td>
<td>CV (skin)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883073812448459">
<p>Abbreviations: CV, curvilinear bodies; (*), died; ERG, electroretinography; F, female; M, male; ND, not done or unknown; TPP1, Tripeptidyl peptidase 1; VEP, visual evoked potentials.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0883073812448459" position="float">
<label>Table 2.</label>
<caption>
<p>Mutations in the CLN2 gene identified in Spanish patients.</p>
</caption>
<graphic alternate-form-of="table2-0883073812448459" xlink:href="10.1177_0883073812448459-table2.tif"/>
<table>
<thead>
<tr>
<th>Case number</th>
<th>Nucleotide change</th>
<th>Mutation</th>
<th>Amino acid change/ predicted consequence</th>
<th>Status</th>
<th>Location</th>
<th>Number of individuals with mutation in the family</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>c.622C&gt;T c.1222-1224del</td>
<td>Nonsense Del 3 bp</td>
<td>p.R208X Frameshift after S408</td>
<td>Compound Heterozygous</td>
<td>Exon 6 Exon 8</td>
<td>1</td>
<td>Sleat et al 1997 This study</td>
</tr>
<tr>
<td>3</td>
<td>c.17+1G&gt;T</td>
<td>Splice site</td>
<td>
</td>
<td>Homozygous</td>
<td>Intron 1</td>
<td>1</td>
<td>Kousi et al 2009</td>
</tr>
<tr>
<td>5</td>
<td>c.880G&gt;A</td>
<td>Missense</td>
<td>p.S293N 2nd mutation not  found</td>
<td>Compound Heterozygous</td>
<td>Exon 7</td>
<td>1</td>
<td>This study</td>
</tr>
<tr>
<td>6</td>
<td>c.797G&gt;A c.1016G&gt;A</td>
<td>Missense Missense</td>
<td>p.R266Q p.R339Q</td>
<td>Compound Heterozygous</td>
<td>Exon 7 Exon 8</td>
<td>1</td>
<td>Milà, personal  communication Pal et al 2009</td>
</tr>
<tr>
<td>7</td>
<td>c.509-1G&gt;A
c.165 C&gt;T</td>
<td>Splice site Missense</td>
<td>p.Q56X</td>
<td>Compound Heterozygous</td>
<td>Intron 5 Exon 3</td>
<td>1</td>
<td>Sleat et al 1997 This study</td>
</tr>
<tr>
<td>8</td>
<td>c.622C&gt;T</td>
<td>Nonsense</td>
<td>p.R208X</td>
<td>Homozygous</td>
<td>Exon 6</td>
<td>2</td>
<td>Sleat et al 1997</td>
</tr>
<tr>
<td>9</td>
<td>c.616C&gt;T c.1506G&gt;C</td>
<td>Missense Splice site</td>
<td>p.R206C</td>
<td>Compound heterozygous</td>
<td>Exon 6 Intron 6</td>
<td>1</td>
<td>Mole et al 1999 This study</td>
</tr>
<tr>
<td>10</td>
<td>c.827A&gt;T</td>
<td>Missense</td>
<td>p.D276V</td>
<td>Homozygous</td>
<td>Exon 7</td>
<td>1</td>
<td>Kohan et al 2009</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section4-0883073812448459">
<title>Regression of Acquired Skills</title>
<p>As shown in <xref ref-type="table" rid="table3-0883073812448459">Table 3</xref>, at the time of the study all patients had lost the ability to speak in full sentences at a median age of 3.7 years (95% CI 3.1-4.3). Loss of walking ability and complete absence of language appeared in 92% of patients at a median age of 4.5 years (95% CI 4.3-4.6 vs 95% CI 4.1-4.8). The median age at which patients became wheelchair bound was quite similar to that which they lost their sitting ability, purposeful hand use and urinary sphincter control. Dysphagia was observed at a median age of 5.4 years (95% CI 4.4-6.3). Kaplan-Meier estimates of the age of the patients at the time of regression of acquired skills are shown in <xref ref-type="fig" rid="fig2-0883073812448459">Figure 2A</xref>.</p>
<fig id="fig2-0883073812448459" position="float">
<label>Figure 2.</label>
<caption>
<p>Kaplan-Meier estimates of the age of the patients at the time of regression of acquired skills (A), epilepsy (B), and main signs and symptoms of the disease (C) among 12 Spanish patients with late infantile neuronal ceroid lipofuscinosis.</p>
</caption>
<graphic alternate-form-of="fig2-0883073812448459" xlink:href="10.1177_0883073812448459-fig2.tif"/>
</fig>
<table-wrap id="table3-0883073812448459" position="float">
<label>Table 3.</label>
<caption>
<p>Age at the time of psychomotor regression, epilepsy, and clinical signs and symptoms.</p>
</caption>
<graphic alternate-form-of="table3-0883073812448459" xlink:href="10.1177_0883073812448459-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="3"> </th>
<th colspan="2"> Patients with late infantile neuronal ceroid lipofuscinosis (n = 12)</th>
</tr>
<tr>
<th>Age, years median</th>
<th>No impairment</th>
</tr>
<tr>
<th>(95% CI)</th>
<th>% patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regression acquired skills</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Loss of walking ability</td>
<td>4.5 (4.3-4.6)</td>
<td>8.3</td>
</tr>
<tr>
<td> Becoming wheelchair-bound</td>
<td>5 (4-5.9)</td>
<td>16.7</td>
</tr>
<tr>
<td> Loss of sitting ability</td>
<td>5 (4.7-5.2)</td>
<td>33.3</td>
</tr>
<tr>
<td> Loss of purposeful hand use</td>
<td>5 (4.4-5.5)</td>
<td>25</td>
</tr>
<tr>
<td> Loss sentences</td>
<td>3.7 (3.1-4.3)</td>
<td>0</td>
</tr>
<tr>
<td> No language</td>
<td>4.5 (4.1-4.8)</td>
<td>8.3</td>
</tr>
<tr>
<td> Dysphagia</td>
<td>5.4 (4.4-6.3)</td>
<td>25</td>
</tr>
<tr>
<td> Urinary incontinence</td>
<td>5 (3.1-6.8)</td>
<td>41.7</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Myoclonic-atonic seizures</td>
<td>4.1 (3.5-4.7)</td>
<td>25</td>
</tr>
<tr>
<td> Myoclonic jerks</td>
<td>3.7 (3.4-4)</td>
<td>0</td>
</tr>
<tr>
<td> Continuous myoclonus</td>
<td>4.7 (4.2-5.2)</td>
<td>8.3</td>
</tr>
<tr>
<td> Partial seizures</td>
<td>3.4 (2.9-3.8)</td>
<td>16.7</td>
</tr>
<tr>
<td> Generalized tonic-clonic</td>
<td>4 (3.3-4.6)</td>
<td>41.7</td>
</tr>
<tr>
<td> Atypical absence seizures</td>
<td>4.3 (3.1-5.4)</td>
<td>33.3</td>
</tr>
<tr>
<td>Clinical signs and symptoms</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Cognitive decline</td>
<td>4 (3.5-4.4)</td>
<td>8.3</td>
</tr>
<tr>
<td> Visual failure</td>
<td>3.8 (3.2-4.4)</td>
<td>16.7</td>
</tr>
<tr>
<td> Blindness</td>
<td>5.1 (4.6-5.6)</td>
<td>8.3</td>
</tr>
<tr>
<td> Tremor</td>
<td>4.2 (3.4-5)</td>
<td>8.3</td>
</tr>
<tr>
<td> Ataxia</td>
<td>4 (3.9-4.1)</td>
<td>0</td>
</tr>
<tr>
<td> Spasticity</td>
<td>4.9 (3.8-5.9)</td>
<td>16.7</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section5-0883073812448459">
<title>Epilepsy</title>
<p>Myoclonic jerks were observed in all patients at a median age of 3.7 years (95% CI 3.4-4) and partial seizures with secondary generalization were reported in 83% of patients at a median of 3.4 years (95% CI 2.9-3.8). Myoclonic-atonic seizures were observed in 75% of patients at a median age of 4.1years (95% CI 3.5-4.7) and generalized tonic-clonic seizures appeared in 58% of patients at a median age of 4 years (95% CI 3.3-4.6). Continuous myoclonus was observed in 92% of patients at a median of 4.7 years (95% CI 4.2-5.2). Kaplan-Meier estimates of the age of the patients at the time of appearance of seizures are shown in <xref ref-type="fig" rid="fig2-0883073812448459">Figure 2B</xref>.</p>
</sec>
<sec id="section6-0883073812448459">
<title>Clinical Signs and Symptoms</title>
<p>The presenting symptoms included seizures (6 patients), delayed speech (5 patients), and clumsiness (1 patient); they were observed between 18 months and 3.7 years of age (mean 2.2 years). Initial seizures were partial status epilepticus (case 4a), partial (case 4b) and simple febrile (case 5) that were followed by myoclonic-atonic seizures (cases 1, 9), myoclonic jerks (case 2), and generalized seizures (case 5) (<xref ref-type="table" rid="table1-0883073812448459">Table 1</xref>).</p>
<p>All patients developed ataxia at a median age of 4 years (95% CI 3.9-4.1), and cognitive decline was observed in 92% of patients at a similar age (median 4 years, 95% CI 3.5-4.4) whereas visual failure appeared at an earlier age (median 3.8 years, 95% CI 3.2-4.4). Tremor occurred in 92% of patients earlier than both spasticity (median age 4.9 years; 95% CI 3.8 - 5.9) and blindness (median age 5.1 years; 95% CI 4.6-5.6). Kaplan-Meier estimates of the age of the patients at the time of appearance of clinical signs and symptoms are shown in <xref ref-type="fig" rid="fig3-0883073812448459">Figure 2C</xref>.</p>
<p>The MRI abnormalities in a patient with late infantile neuronal ceroid lipofuscinosis are shown in <xref ref-type="fig" rid="fig4-0883073812448459">Figure 3</xref>.</p>
<fig id="fig3-0883073812448459" position="float">
<label>Figure 2 (Continued).</label>
<graphic alternate-form-of="fig3-0883073812448459" xlink:href="10.1177_0883073812448459-fig3.tif"/>
</fig>
<fig id="fig4-0883073812448459" position="float">
<label>Figure 3.</label>
<caption>
<p>Patient 8a at 3 years 8 months (A-B) and 4 years 6 months of age (C-D). Sagittal T1(A) and axial fluid-attenuated inversion recovery sections (B) showing mild cerebellar atrophy and a subtle increase in the periventricular white matter signal intensity. Sagittal T1(C) and axial fluid-attenuated inversion recovery sections (D) showing progression of the cerebellar and the supratentorial atrophy. The abnormal periventricular white matter signal intensity becomes more obvious.</p>
</caption>
<graphic alternate-form-of="fig4-0883073812448459" xlink:href="10.1177_0883073812448459-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section7-0883073812448459">
<title>Discussion</title>
<p>Late infantile neuronal ceroid lipofuscinosis occurs worldwide and it seems to be less frequent compared to the juvenile form in Spain.<sup>
<xref ref-type="bibr" rid="bibr22-0883073812448459">22</xref>
</sup> The main clinical features and ultrastructural data of this disease have been previously described.<sup>
<xref ref-type="bibr" rid="bibr8-0883073812448459">8</xref>,<xref ref-type="bibr" rid="bibr24-0883073812448459">24</xref>
</sup> However, there have been no reports of the rate of disease progression and its correlation with mutations in the <italic>CLN2</italic> gene in our country.</p>
<p>Our series was quite homogeneous both clinically and pathologically whereas clinical heterogeneity in late infantile neuronal ceroid lipofuscinosis has been previously described.<sup>
<xref ref-type="bibr" rid="bibr25-0883073812448459">25</xref>
</sup> The age at onset of the disease ranged between 18 months and 3.7 years (mean 2.2 years), similar to what has been previously described by Topcu et al<sup>
<xref ref-type="bibr" rid="bibr26-0883073812448459">26</xref>
</sup> and other authors have reported onset between 2 and 3.5 years<sup>
<xref ref-type="bibr" rid="bibr27-0883073812448459">27</xref>
</sup> and up to 4 years.<sup>
<xref ref-type="bibr" rid="bibr14-0883073812448459">14</xref>,<xref ref-type="bibr" rid="bibr28-0883073812448459">28</xref>
</sup>
</p>
<p>Careful clinical assessment regarding the regression of acquired skills allowed us to observe that it may be initiated by the onset of loss of sentences by 3 years of age. During the second stage of the disease, patients lost their walking ability and showed nonverbal communication. Finally, patients lost their sitting ability, purposeful hand use, and urinary control sphincter and became wheelchair-bound at a median age of 5 years<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448459">2</xref>
</sup> followed by dysphagia within a few months.</p>
<p>The initial manifestations of the disease were delayed speech development in patients who never completely acquired language capacity<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448459">2</xref>,<xref ref-type="bibr" rid="bibr8-0883073812448459">8</xref>,<xref ref-type="bibr" rid="bibr29-0883073812448459">29</xref>
</sup> and simple febrile seizures followed by epilepsy as reported occasionally.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812448459">12</xref>,<xref ref-type="bibr" rid="bibr28-0883073812448459">28</xref>
</sup> An initial diagnosis of late infantile neuronal ceroid lipofuscinosis patients may be suspected in the presence of regression or delayed speech.</p>
<p>Most authors have described epilepsy, which may be manifested by any type of seizures as the presenting symptom between 2 and 4 years of age<sup>
<xref ref-type="bibr" rid="bibr10-0883073812448459">10</xref>,<xref ref-type="bibr" rid="bibr14-0883073812448459">14</xref>,<xref ref-type="bibr" rid="bibr26-0883073812448459">26</xref>,<xref ref-type="bibr" rid="bibr30-0883073812448459">30</xref>
<xref ref-type="bibr" rid="bibr31-0883073812448459"/>
<xref ref-type="bibr" rid="bibr32-0883073812448459"/>
<xref ref-type="bibr" rid="bibr33-0883073812448459"/>–<xref ref-type="bibr" rid="bibr34-0883073812448459">34</xref>
</sup> (median 3 years).<sup>
<xref ref-type="bibr" rid="bibr35-0883073812448459">35</xref>
</sup> The estimated median age at onset of partial seizures by age 3.4 years, followed by myoclonic jerks that occurred between 3 and 4 years of age in our patients, was similar to what previously has been reported. The clinical course of progressive myoclonic epilepsy became evident in the series during follow-up. Generalized tonic-clonic seizures have been reported as the most prominent seizure type of the disease<sup>
<xref ref-type="bibr" rid="bibr26-0883073812448459">26</xref>
</sup> and may be preceded by simple febrile seizures.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812448459">12</xref>,<xref ref-type="bibr" rid="bibr28-0883073812448459">28</xref>
</sup> In contrast, in the series generalized tonic-clonic seizures were less frequent. Epileptic seizures were absent in one late infantile neuronal ceroid lipofuscinosis patient with protracted clinical course.<sup>
<xref ref-type="bibr" rid="bibr13-0883073812448459">13</xref>
</sup> All these data suggest that the spectrum of epilepsy in patients with late infantile neuronal ceroid lipofuscinosis may be surprisingly broad.</p>
<p>Electroencephalographic findings in most patients showed spikes and slow waves superimposed on irregular slow background activity on both hemispheres, mostly in the posterior regions, during the course of the disease.<sup>
<xref ref-type="bibr" rid="bibr36-0883073812448459">36</xref>
</sup> In contrast to other authors, polyphasic high-voltage posterior spikes when photic stimulation was performed at low frequency were not observed in the series.<sup>
<xref ref-type="bibr" rid="bibr30-0883073812448459">30</xref>,<xref ref-type="bibr" rid="bibr37-0883073812448459">37</xref>,<xref ref-type="bibr" rid="bibr38-0883073812448459">38</xref>
</sup>
</p>
<p>In the present study, visual failure appeared after the onset of epilepsy<sup>
<xref ref-type="bibr" rid="bibr32-0883073812448459">32</xref>,<xref ref-type="bibr" rid="bibr35-0883073812448459">35</xref>
</sup> and it has been reported at a median age of 4 years<sup>
<xref ref-type="bibr" rid="bibr35-0883073812448459">35</xref>
</sup> leading to blindness by 5 or 6 years.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812448459">10</xref>,<xref ref-type="bibr" rid="bibr24-0883073812448459">24</xref>
</sup>
</p>
<p>Ataxia was the third symptom of the disease after the onset of epilepsy<sup>
<xref ref-type="bibr" rid="bibr38-0883073812448459">38</xref>
</sup> and visual failure in the series, and it occurred at a similar median age as that of cognitive decline (4 years) although it may appear earlier (median 3.5 years, range 2.5-4.6) in patients with late infantile neuronal ceroid lipofuscinosis.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448459">2</xref>
</sup> Severe motor impairment with hand tremor and spasticity was observed at advanced stages of the disease in our patients.</p>
<p>We were not able to apply the rating scales of disease severity (scale developed by Steinfeld et al 2002; modified Hamburg Late Infantile Neuronal Ceroid Lipofuscinosis Scale and Weill Cornell Late Infantile Neuronal Ceroid Lipofuscinosis Scale)<sup>
<xref ref-type="bibr" rid="bibr20-0883073812448459">20</xref>,<xref ref-type="bibr" rid="bibr21-0883073812448459">21</xref>
</sup> because most patients had died and the remaining 3 patients were in an advanced stage of the disease at the time the authors undertook this study.</p>
<p>Only a few studies have described neuroradiologic imaging in living patients with late infantile neuronal ceroid lipofuscinosis, demonstrating progressive gray matter atrophy prominent in the infratentorial regions. Brain MRI findings in the series were similar to previous reports.<sup>
<xref ref-type="bibr" rid="bibr31-0883073812448459">31</xref>,<xref ref-type="bibr" rid="bibr33-0883073812448459">33</xref>,<xref ref-type="bibr" rid="bibr39-0883073812448459">39</xref>
</sup>
</p>
<p>The relationship between the absence of tripeptidyl peptidase 1 activity and curvilinear bodies<sup>
<xref ref-type="bibr" rid="bibr9-0883073812448459">9</xref>,<xref ref-type="bibr" rid="bibr19-0883073812448459">19</xref>,<xref ref-type="bibr" rid="bibr40-0883073812448459">40</xref>
</sup> and mutations in <italic>CLN2</italic> gene and curvilinear bodies has been reported.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812448459">3</xref>,<xref ref-type="bibr" rid="bibr8-0883073812448459">8</xref>
</sup> The present results confirm that mutations in the <italic>CLN2</italic> gene are associated with reduced tripeptidyl peptidase 1 activity in late infantile neuronal ceroid lipofuscinosis, as previously reported.<sup>
<xref ref-type="bibr" rid="bibr19-0883073812448459">19</xref>
</sup> According to the present results, 2 of the <italic>CLN2</italic> mutations identified by Sleat et al (1997)<sup>
<xref ref-type="bibr" rid="bibr7-0883073812448459">7</xref>
</sup> were less frequent (78% vs 26%) than previously reported in other studies.<sup>
<xref ref-type="bibr" rid="bibr18-0883073812448459">18</xref>
<xref ref-type="bibr" rid="bibr19-0883073812448459"/>
<xref ref-type="bibr" rid="bibr20-0883073812448459"/>–<xref ref-type="bibr" rid="bibr21-0883073812448459">21</xref>
</sup> This may be due to the higher genetic heterogeneity present in the Spanish population, which is well known in other recessive diseases.</p>
<p>On the other hand, in agreement with Kohan et al (2009)<sup>
<xref ref-type="bibr" rid="bibr14-0883073812448459">14</xref>
</sup> the presence of the p.D276V missense mutation was found in homozygosis in 1 Paraguayan patient, in agreement with other cases of Latin American origin.</p>
<p>In summary, the clinical progression of late infantile neuronal ceroid lipofuscinosis in the study population was relatively homogeneous. Genetic heterogeneity of late infantile neuronal ceroid lipofuscinosis was demonstrated in the 10 families studied. The knowledge of the natural history of the disease can provide basic information for designing health care plans and to prepare for future clinical trials.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work has been approved by the responsible authorities of Hospital Sant Joan de Déu, which was the reference hospital for the study.</p>
<p>The authors are grateful to Drs M. Rebollo and MI. Alonso Colmenero and the Spanish Association of Families Affected by NCL for the valuable support and indispensable cooperation. Statistical support was provided by Raquel Iniesta (Fundació Sant Joan de Déu, ISCIII CA08/00151).</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073812448459">
<label>Author Contributions</label>
<p>MSP-P contributed to the design of the study, reviewed the medical records, took part in the analysis and interpretation the data, wrote the first draft, and prepared the final draft of the manuscript. She had full access to study data and takes responsibility for the integrity of the study. MPM contributed to the design of the study and acquisition of data, participated in the statistical analysis, interpretation of data, writing of the manuscript, and approved the final draft. IFA performed histopathologic studies, contributed to analysis of data and drafting, reviewed the manuscript for intellectual content, and approved the final draft. LRR contributed to genetic studies and approved the final draft. VCS performed histopathologic studies and approved the final draft. MJMG, JEP, AVP, MMGG, AMB, and EMH provided case histories for the study, acquired data, reviewed the manuscript for intellectual content, and approved the final draft. MJCR and LG performed enzymatic studies, reviewed the manuscript for intellectual content, and approved the final draft. MMR was the principal investigator, performed the genetic studies, contributed to the design of the study and acquisition of data, participated in writing of the manuscript and approved the final draft. She had full access to study data and takes responsibility for the integrity of the study, and controlled the decision to publish.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073812448459">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073812448459">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="other" id="fn4-0883073812448459">
<label>Ethical Approval</label>
<p>The study was approved by the Ethics Committee of Hospital Sant Joan de Déu in Barcelona.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812448459">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>The neuronal ceroid-lipofuscinoses. Recent advances</article-title>. <source>Brain Pathol</source>. <year>1998</year>;<volume>8</volume>:<fpage>151</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812448459">
<label>2</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Gottlob</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>BD</given-names>
</name>
<etal/>
</person-group>. <article-title>CLN2, Classic late infantile NCL</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>BD</given-names>
</name>
</person-group>, eds. <source>The Neuronal Ceroid Lipofuscinosis (Batten Disease). On behalf of the European Concerted Action Group</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>IOS Press</publisher-name>; <year>1999</year>:<fpage>37</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812448459">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Kida</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Connell</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Neuronal ceroid lipofuscinoses: research update</article-title>. <source>Neurol Sci</source>. <year>2000</year>;<volume>21</volume>(<issue>3suppl</issue>):<fpage>S49</fpage>–<lpage>S56</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812448459">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claussen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heim</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Knispel</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence of neuronal ceroid-lipofuscinoses in West Germany: variation of a method for studying autosomal recessive disorders</article-title>. <source>Am J Med Genet</source>. <year>1992</year>;<volume>42</volume>:<fpage>536</fpage>–<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812448459">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uvebrant</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hagberg</surname>
<given-names>B.</given-names>
</name>
</person-group> <article-title>Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures</article-title>. <source>Neuropediatrics</source>. <year>1997</year>;<volume>28</volume>:<fpage>6</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812448459">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharp</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>BD</given-names>
</name>
<etal/>
</person-group>. <article-title>Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21-23</article-title>. <source>Hum Mol Genet</source>. <year>1997</year>;<volume>6</volume>:<fpage>591</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812448459">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sleat</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lackland</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis</article-title>. <source>Science</source>. <year>1997</year>;<volume>277</volume>:<fpage>1802</fpage>–<lpage>1805</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812448459">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
</person-group>. <article-title>Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses</article-title>. <source>Neurogenetics</source>. <year>2005</year>;<volume>6</volume>:<fpage>107</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812448459">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Philippart</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Pheno/genotypic correlations of neuronal ceroid lipofuscinoses</article-title>. <source>Neurology</source>. <year>2001</year>;<volume>57</volume>:<fpage>576</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812448459">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haltia</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The neuronal ceroid-lipofuscinoses</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2003</year>;<volume>62</volume>:<fpage>1</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812448459">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Kaczmarski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kida</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations</article-title>. <source>Mol Genet Metab</source>. <year>1999</year>;<volume>66</volume>:<fpage>248</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812448459">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartikainen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
<etal/>
</person-group>. <article-title>Late infantile neuronal ceroid lipofuscinosis is due to splicing mutations in the CLN2 gene</article-title>. <source>Mol Genet Metab</source>. <year>1999</year>;<volume>67</volume>:<fpage>162</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812448459">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elleder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dvorakova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stolnaja</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency</article-title>. <source>Acta Neuropathol</source>. <year>2008</year>;<volume>116</volume>:<fpage>119</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812448459">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cismondi</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients</article-title>. <source>Clin Genet</source>. <year>2009</year>;<volume>76</volume>:<fpage>372</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812448459">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bessa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Texeira</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>CLN2/TPP1 deficiency: the novel mutation IVS7-10A&gt;G causes intron retention and is associated with a mild disease phenotype</article-title>. <source>Mol Genet Metab</source>. <year>2008</year>;<volume>93</volume>:<fpage>66</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812448459">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of novel CLN2 mutations shows Canadian specific NCL2 alleles</article-title>. <source>J Med Genet</source>. <year>2002</year>;<volume>39</volume>:<fpage>822</fpage>–<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812448459">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simonati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santorum</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tessa</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A CLN2 gene nonsense mutation is associated with severe caudate atrophy and dystonia in LINCL</article-title>. <source>Neuropediatrics</source> <year>2000</year>;<volume>31</volume>:<fpage>199</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812448459">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Hartikainen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Two common mutations in the CLN2 gene underlie late infantile neuronal ceroid lipofuscinosis</article-title>. <source>Clin Genet</source>. <year>1998</year>;<volume>54</volume>:<fpage>234</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812448459">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sleat</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Gin</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Sohar</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder</article-title>. <source>Am J Hum Genet</source>. <year>1999</year>;<volume>64</volume>:<fpage>1511</fpage>–<lpage>1523</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812448459">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinfeld</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heim</surname>
<given-names>P</given-names>
</name>
<name>
<surname>von Gregory</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations</article-title>. <source>Am J Med Genet</source>. <year>2002</year>;<volume>112</volume>:<fpage>347</fpage>–<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812448459">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worgall</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kekatpure</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Heier</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurological deterioration in late infantile neuronal ceroid lipofuscinosis</article-title>. <source>Neurology</source>. <year>2007</year>;<volume>69</volume>:<fpage>521</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812448459">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Poyato</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Mila Recansens</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ferrer Abizanda</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Juvenile neuronal ceroid lipofuscinosis: clinical course and genetic studies in Spanish patients</article-title>. <source>J Inherit Metab Dis</source>. <year>2011</year>;<volume>34</volume>:<fpage>1083</fpage>–<lpage>1093</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812448459">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowry</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Rosebrough</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Farr</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Randall</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Protein measurement with the Folin phenol reagent</article-title>. <source>J Biol Chem</source>. <year>1951</year>;<volume>193</volume>:<fpage>265</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812448459">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
</person-group>. <article-title>Current state of clinical and morphological features in human NCL</article-title>. <source>Brain Pathol</source>. <year>2004</year>;<volume>14</volume>:<fpage>61</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812448459">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Moroziewicz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Heterogeneity of late-infantile neuronal ceroid lipofuscinosis</article-title>. <source>Genet Med</source>. <year>2000</year>;<volume>2</volume>:<fpage>312</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812448459">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Topcu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yalnizoglu</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies</article-title>. <source>Turk J Pediatr</source>. <year>2004</year>;<volume>46</volume>:<fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812448459">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elleder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Franc</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Neuronal ceroid lipofuscinosis in the Czech Republic: analysis of 57 cases. Report of the “Prague NCL group.”</article-title> <source>Eur J Paediatr Neurol</source>. <year>1997</year>;<volume>1</volume>:<fpage>109</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812448459">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barisic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Logan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pikija</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis</article-title>. <source>Croat Med J</source>. <year>2003</year>;<volume>44</volume>:<fpage>489</fpage>–<lpage>493</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812448459">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santavuori</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vanhanen</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Autti</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders</article-title>. <source>Eur J Paediatr Neurol</source>. <year>2001</year>;<volume>5</volume>(<issue>suppl A</issue>):<fpage>157</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812448459">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KC</given-names>
</name>
</person-group>. <article-title>Classic late infantile neuronal ceroid lipofuscinosis in a Chinese patient</article-title>. <source>Hong Kong Med J</source>. <year>2001</year>;<volume>7</volume>:<fpage>93</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812448459">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavrov</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Ilyna</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Zakharova</surname>
<given-names>EY</given-names>
</name>
<etal/>
</person-group>. <article-title>The first three Russian cases of classical, late-infantile, neuronal ceroid lipofuscinosis</article-title>. <source>Eur J Paediatr Neurol</source>. <year>2002</year>;<volume>6</volume>:<fpage>161</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812448459">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teixeira</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guimaraes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bessa</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinicopathological and molecular characterization of neuronal ceroid lipofuscinosis in the Portuguese population</article-title>. <source>J Neurol</source>. <year>2003</year>;<volume>250</volume>:<fpage>661</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812448459">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koul</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Al-Futaisi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ganesh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rangnath Bushnarmuth</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Late-infantile neuronal ceroid lipofuscinosis (CLN2/Jansky-Bielschowsky type) in Oman</article-title>. <source>J Child Neurol</source>. <year>2007</year>;<volume>22</volume>:<fpage>555</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812448459">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>XW</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis</article-title>. <source>Neurogenetics</source>. <year>2011</year>;<volume>12</volume>:<fpage>93</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr35-0883073812448459">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>MacMillan</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland</article-title>. <source>Clin Genet</source>. <year>2008</year>;<volume>74</volume>:<fpage>213</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr36-0883073812448459">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veneselli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Biancheri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Buoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fois</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis</article-title>. <source>Brain Dev</source>. <year>2001</year>;<volume>23</volume>:<fpage>306</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr37-0883073812448459">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pampiglione</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Harden</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Neurophysiological identification of a late infantile form of “neuronal lipidosis.”</article-title> <source>J Neurol Neurosurg Psychiatry</source>. <year>1973</year>;<volume>36</volume>:<fpage>68</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr38-0883073812448459">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Bang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>YG</given-names>
</name>
<etal/>
</person-group>. <article-title>A case of late infantile neuronal ceroid lipofuscinosis</article-title>. <source>Yonsei Med J</source>. <year>2003</year>;<volume>44</volume>:<fpage>331</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr39-0883073812448459">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Handwerker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huppertz</surname>
<given-names>HI</given-names>
</name>
</person-group>. <article-title>Neuroradiological findings in classical late infantile neuronal ceroid-lipofuscinosis</article-title>. <source>Pediatr Neurol</source>. <year>1996</year>;<volume>15</volume>:<fpage>344</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr40-0883073812448459">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofmann</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Atashband</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>SK</given-names>
</name>
<etal/>
</person-group>. <article-title>Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2)</article-title>. <source>Curr Mol Med</source>. <year>2002</year>;<volume>2</volume>:<fpage>423</fpage>–<lpage>437</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>